Princess Alexandra Hospital Southside Clinical Unit
Faculty of Medicine
Availability:
Available for supervision
Stefan is a Staff Specialist in Neurology at the Princess Alexandra Hospital (PAH) and the Mater Centre for Neuroscience. He finished his training as neurologist in 2012.
He runs dedicated multiple sclerosis (MS) and Neuroimmunology clinics at the PAH, leading in modern MS therapies. Moreover, he has been at the forefront of advancing the field of neuroimmunology in Queensland, with establishment of dedicated neuroimmunology outpatient clinics at the RBWH and PAH, combining expertise from neurologists and immunologists in the care of this very complex group of disorders.
In addition to his busy, full-time clinical workload, Stefan has been involved as PI or CI in a range of clinical trials in the fields of MS, botulinum toxin, CIDP and Pompe’s disease. Additionally, he has performed and is involved in ongoing research projects of neuroimmunological disorders such as neuromyelitis optica, myasthenia gravis and autoimmune limbic encephalitis. He has been a member of the New Horizons study to assess prevalence of anti-neuronal antibodies in patients with new onset psychosis.
Prior to this, Stefan finished a PhD in the field of ‘Immunogenetics of Guillain-Barre Syndrome and Chronic inflammatory polyneuropathy’ at the University of Queensland in 2014. He also completed a doctoral thesis at the University of Heidelberg, Germany in 2002 in the field of T cell immunology. During this time, he has developed solid skills in bench-side immunological research.
Currently, he is neurological lead in a diverse group of clinicians and scientists investigating the role of antineuronal antibodies in neurological and psychiatric disease. He supervises 3 PhD students in the field of advanced imaging in autoimmune encephalitis and multiple sclerosis. He is currently building up a laboratory to test antineuronal antibodies using live cell assays.
Dr Andrew Brooks is the Group Leader of the Cytokine Receptor Signalling Group at the University of Queensland Diamantina Institute (UQ DI) within the Translational Research Institute. Andrew completed his Honours research on Flaviviruses in 1996 at the Department of Microbiology and Immunology at James Cook University and then moved to the Department of Biochemistry to study Dengue Virus where he completed his PhD in 2002. He then moved to St Jude Children’s Research Hospital in Memphis, TN, USA where he researched the role of Epstein-Barr Virus in B-cell lymphomagenesis. He then joined the research group headed by Prof Michael Waters at the Institute for Molecular Bioscience, UQ in 2006 and subsequently began his independent research group at UQ DI in 2014. Andrew’s research interests are in cytokine receptors, cell signalling, oncogenesis, and immunology. His current research focus is on the molecular mechanisms of class I cytokine receptor activation including the growth hormone receptor (GHR), thrombopoietin receptor (TpoR/MPL), IL-7 receptor, and IL-6 receptor (IL-6R). In addition, he is investigating the regulation of inflammation by HLA-G. His research has led to publications in journals including Science, Blood, Hepatology, Oncogene, Nature Cell Biology, and PNAS. He has been the secured of over $12 million in research and commercialisation funding from sources including NHMRC, ARC, Innovation Connections, and Merck. He has a number of national and international collaborations, a scientific founder of a start-up company, and is an Editorial Board member for the Journal Cancers and Human Cell. He was previously a committee member of Australian Early-Mid Career Researchers Forum (AEMCRF) launched by the Australian Academy of Science.
Associate Professor Emma Hamilton-Williams’ career focuses on understanding how immune tolerance is disrupted leading to the development of the autoimmune disease type 1 diabetes. She received her PhD from the Australian National University in 2001, followed by postdoctoral training in Germany and the Scripps Research Institute in the USA.
In 2012, she started a laboratory at the Frazer Institute, University of Queensland where she investigates the gut microbiota as a potential trigger or therapy target for type 1 diabetes, as well as developing an immunotherapy for type 1 diabetes. The overall aim of her research is to find new ways to prevent or treat the underlying immune dysfunction causing autoimmunity.
She is Chief Scientific Officer for an Australia-wide pregnancy-birth cohort study of children at increased risk of type 1 diabetes, which aims to uncover the environmental drivers of this disease. Her laboratory uses big-data approaches including proteomics, metabolomics and metagenomics to understand the function of the gut microbiota linked to disease.
She recently conducted a clinical trial of a microbiome-targeting biotherapy aimed at restoring a healthy microbiome and immune tolerance, with an ultimate aim of preventing type 1 diabetes.
Dr. Sherman Leung is the Head of Research Operations at Wesley Research Institute - the official research partner for UnitingCare encompassing the four UnitingCare hospitals in Queensland as well as Lifeline, Blue Care, and Family and Disability Services. He is a PhD trained scientist, conducting his research training at The University of Queensland.
His research is published in highly regarded peer-reviewed journals, including recently in 'Diabetes', receiving the Cover Image, an 'In This Issue' feature, and shared across the Australian-wide 7 Network news. He has extensive experience in clinical trials, having worked at Microba Life Sciences, an ASX-listed biotechnology start-up, and Nucleus Network, Australia’s largest early phase clinical trial site having overseen the conduct of several high-profile COVID-19 projects including that of Nuvaxovid by Novavax that is now authorised for use by the TGA, EMEA & FDA across many jurisdictions worldwide.
At Wesley Research Institute, he is responsible for the Clinical Trials Centre, Biobank, Research Office and all research programs across the health and medical sciences. He contributes his time to numerous initiatives in the industry including being on the Editorial Board for 'Trials', being a former member of the Metro North Human Research Ethics Committee (HREC), and classrooms on clinical trials, informed consent and ethics to medical and postgraduate students at The University of Queensland.
Dr. Kelvin Tuong is a Senior Research Fellow/Group Leader at the Ian Frazer Centre for Children’s Immunotherapy Research (IFCCIR), Child Health Research Centre. He is interested in single-cell analysis of immune cells and harnessing adaptive immune receptors for understanding immune cell development and function in health and in cancer.
Dr. Tuong was born and raised in Singapore and moved to Brisbane, Australia, after completing national service in Singapore and obtaining a Diploma in Biomedical Laboratory Technology (Ngee Ann Polytechnic).
Dr. Tuong was originally trained as a molecular cell biologist and gradually transitioned into bioinformatics during his post-doctoral training. He has been very prolific for an early career researcher, having published >50 articles since 2013, with nearly a third of them as first/co-first or last author and has a stellar track record of pushing out highly collaborative work in prestigious journals including Nature, Cell, Science, Nature Medicine, Nature Biotechnology J Exp Med etc. He has the rare combination of having excellent laboratory and bioinformatics skill sets which provide him a strong command of both fundamental immunology and computational approaches.
Dr. Tuong completed his undergraduate Bachelor's degree in Biomedical science with Class I Honours, followed by his PhD in macrophage cell biology and endocrinology at UQ (Prof. Jenny Stow lab and Emiritus Prof. George Muscat lab, IMB, UQ). He then went on to a post-doc position with Emiritus Prof. Ian Frazer (co-inventor of the Gardasil cervical cancer vaccine, UQ Frazer Institute, Translational Research Institute) where he worked on HPV immunology, cervical cancer and skin cancer. In his time in the Frazer lab, he developed an interest in bioinformatics analyses as a means to tackle and understanding immunology problems in health and disease. He then moved to the UK and joined Prof. Menna Clatworthy's lab at the University of Cambridge and Dr. Sarah Teichmann's lab at the Wellcome Trust Sanger Institute. He has focused his interests on single-cell analyses of tissue immune cells, including T and B cells and their specific receptors (TCR/BCR). He has developed bespoke bioinformatics software, including one tailored for single-cell B Cell Receptor sequencing analysis, Dandelion, which he used in one of the largest combined single-cell transcriptomic, surface proteomic and TCR/BCR sequencing dataset in the world, published in Nature Medicine, and more recently in Nature Biotechnology where we introduced a TCR-based pseudotime trajectory analysis method.
Dr. Tuong is now leading the Computational Immunology group at the IFCCIR and his lab is focused on investigating how pediatric immunity is perturbed during cancer at the cellular level and how this information can be used for creating novel warning systems for children with cancer. For potential students/post-docs/trainees interested in joining the team, please contact Dr. Tuong at z.tuong@uq.edu.au.
Dr Ran Wang graduated with her PhD in 2015, and after undertaking a postdoc position in Scripps Research, USA returned to Australia in 2017. She is now a Senior Postdoctoral Researcher supported by the prestigious Bushell Postdoctoral Research Fellowship from the Gastroenterology Society of Australia. Dr Wang is interested to understand the nature of inflammation in gut and lung and investigate the local and systemic impacts of chronic gut inflammation. In addition to a growing track-record in the mucosal immunology field, she is also building an inter-disciplinary research profile in material science and nanotechnology for drug delivery and immune modulation. She is the Associate Editor of Frontier of Cellular and Infection Microbiology Journal since 2018.